Time from admission to randomization and the effect of empagliflozin in acute heart failure: A post-hoc analysis from EMPULSE.
Saved in:
| Title: | Time from admission to randomization and the effect of empagliflozin in acute heart failure: A post-hoc analysis from EMPULSE. |
|---|---|
| Authors: | Ferreira JP; Centre d'Investigations Cliniques Plurithématique 1433, INSERM, Université de Lorraine, Nancy, France.; F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), INSERM U1116, Centre Hospitalier Régional Universitaire de Nancy, Nancy, France.; UnIC@RISE, Cardiovascular Research and Development Center, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto, Portugal., Blatchford JP; Elderbrook Solutions GmbH, Sky Tower, Borsigstr. 4, D-74321 Bietigheim-Bissingen, Germany on behalf of Boehringer Ingelheim, Pharma GmbH & Co. KG, Biberach, Germany., Teerlink JR; Section of Cardiology, San Francisco Veterans Affairs Medical Center and School of Medicine, University of California, San Francisco, San Francisco, CA, USA., Kosiborod MN; Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City, Kansas City, MO, USA., Angermann CE; Comprehensive Heart Failure Center Würzburg, Department of Medicine 1, University Hospital Würzburg, Würzburg, Germany., Biegus J; Institute of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland., Collins SP; Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.; Geriatric Research and Education Clinical Care, Tennessee Valley Healthcare Facility VA Medical Center, Nashville, TN, USA., Tromp J; Saw Swee Hock School of Public Health, National University of Singapore, the National University Health System, Singapore, Singapore., Nassif ME; Saint Luke's Mid America Heart Institute and the University of Missouri, Kansas City, MO, USA., Psotka MA; Inova Heart and Vascular Institute, Falls Church, VA, USA., Comin-Colet J; Hospital Universitari de Bellvitge, University of Barcelona, IDIBELL and CIBERCV, Barcelona, Spain., Mentz RJ; Duke Clinical Research Institute and Division of Cardiology, Duke University Medical Center, Durham, NC, USA., Brueckmann M; Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.; First Department of Medicine, Faculty of Medicine Mannheim, University of Heidelberg, Mannheim, Germany., Nordaby M; Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany., Ponikowski P; Institute of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland., Voors AA; Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. |
| Source: | European journal of heart failure [Eur J Heart Fail] 2024 Sep; Vol. 26 (9), pp. 1976-1983. Date of Electronic Publication: 2024 Jul 09. |
| Publication Type: | Journal Article; Randomized Controlled Trial |
| Journal Info: | Publisher: Wiley Country of Publication: England NLM ID: 100887595 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0844 (Electronic) Linking ISSN: 13889842 NLM ISO Abbreviation: Eur J Heart Fail Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
